EGFR and glioblastoma: In the treatment of GBM, a targeted drug D2C7-IT, comprising of the EGFR-targeted recognition moiety linked to a recombinant pseudomonas exotoxin A, showed promising results in preclinical studies [149] and now patients are being recruited for the evaluation of the drug’s safety and efficacy in Phase I and II clinical trials NCT04547777 and NCT05734560;